EirGenix Inc. (6589 TW) stock market data APIs
NT$57.1818
-0.38(-0.7%)
as of April 2, 2026
Try our APIs with
free plan!
EirGenix Inc. Financial Data Overview
Price chart is built with
Anychart
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Prev. Close
57.1818
Open
56.8033
High
58.1097
Low
56.7562
52 wk Range
52.7-84.3
Market Cap
17 342 M
Shares Outstanding
303 M
Revenue
1 005 M
EPS
-0.2
Beta
0.674
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with EirGenix Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EirGenix Inc. data using free add-ons & libraries
Get EirGenix Inc. Fundamental Data
EirGenix Inc. Fundamental data includes:
- Net Revenue: 1 005 M
- EBITDA: -560 312 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EirGenix Inc. News
New
Exclusive Biosimilar License With EirGenix Might Change The Case For Investing In Sandoz Group (SWX:SDZ)
On November 12, 2025, EirGenix Inc. announced a global license agreement granting Sandoz Group exclusive worldwide commercial rights (excluding select Asian markets) to a proposed biosimilar of oncolo...
Sandoz (SWX:SDZ) Valuation in Focus as Exclusive Pertuzumab Biosimilar Deal Expands Oncology Ambitions
Sandoz Group (SWX:SDZ) has secured exclusive global rights to commercialize a biosimilar version of pertuzumab, following a milestone-based agreement with EirGenix Inc. This move signals a meaningful ...
/C O R R E C T I O N -- EirGenix, Inc./
In the news release, EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A, issued 12-Nov-2025 by EirGenix, Inc. over PR Newswire, we are advised by the com...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (S...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
